By Tony Fong

NEW YORK (GenomeWeb News) – As Epigenomics prepares to enter the US market, it plans to meet with the US Food and Drug Administration in the coming weeks and to hire someone to direct its commercial operations in the US.

On the sidelines of the JP Morgan Healthcare Conference last week in San Francisco, an official from the German molecular diagnostics firm outlined the company's plan to break into the US market with its lead product, the Epi proColon test for the early detection of colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.